



Pixium Vision receives the 2016 *Observeur du design* Award for IRIS[®], its first Vision Restoration System

Paris, France – December 11, 2015 – Pixium Vision (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, today announced that it has received the 2016 *Observeur du design* award, alongside the Silamir Group's design division, for IRIS[®], the company's first Vision Restoration System (VRS).

Selected as "*most notable creation*" by a jury of designers and industrial professionals, the IRIS[®] VRS is designed for patients with retinitis pigmentosa, a genetic disease that leads to progressive degeneration of the retina's photoreceptors. The compact and ergonomic design of the system, comprised of a pair of glasses equipped with a smart neuromorphic mini-camera and a pocket computer, presented a challenge for the design teams.

For **Khalid Ishaque, CEO of Pixium Vision**, "*This award illustrates our patient centric approach in terms of comfort, ergonomics and aesthetics. It reflects the Design Award philosophy for the selected object to respond a complex needs by integrating creativity, intuition and emotion.*"

The IRIS[®] is exhibited at the Cité des Sciences et de l'Industrie in Paris.

About the Observeur du Design www.icsid.org/about/about.htm



Created in 1999 by l'APIC – the Association for the Promotion of Industrial Creation -, the *Observeur du design* is a **prestigious French design award** that highlights the talent of companies and designers. It is renowned and supported the French Ministry of Economy, Industry and Information Technology and the International Council of Societies of Industrial Design (ICSID). www.icsid.org/about/about.htm

About Pixium Vision (www.pixium-vision.com)

Pixium Vision is developing innovative Vision Restoration Systems (VRS) that aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. The Company harnesses the rapid advances in visual processing, microelectronics / nanoelectronics, optoelectronics, neurobiology and intelligent software algorithms. Pixium Vision's VRS are associated with a surgical intervention as well as a rehabilitation period.

Clinical trials are currently underway with the VRS IRIS[®] in several centers in Europe. Patients have tolerated their implants well so far and improvements in visual perception have been observed. Pixium Vision plans to file IRIS's CE mark dossier before the end of 2015 and expects to launch IRIS[®] during the first half of 2016.

Pixium Vision is also developing PRIMA, a sub retinal implant currently in preclinical trial. The Company plans to begin clinical trials of PRIMA in Europe in 2016.

The company is ISO 13485 certified.



Pixium Vision is listed on Euronext (Compartiment C) in Paris.
ISIN: FR0011950641; Mnemo: PIX

IRIS® is a trademark of Pixium-Vision SA

Contacts

Pixium Vision

Pierre Kemula, CFO

investors@pixium-vision.com

+33 1 76 21 47 30

 [@PixiumVision](https://twitter.com/PixiumVision)

Media Relations

Newcap

Annie-Florence Loyer - afloyer@newcap.fr

[+33 1 44 71 00 12](tel:+33144710012) / [+33 6 88 20 35 59](tel:+33688203559)

Daphné Boccara - dboccara@newcap.fr

[+33 1 44 71 94 93](tel:+33144719493)

Disclaimer:

This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.

Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.

For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company's Registration Document filed with the AMF under number R15-069 on September 23, 2015 which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).